A meta-analysis of RCTs in adults with type 1 diabetes showed an increased probability of DKA with SGLT-2 inhibitor therapy compared with placebo (odds ratio 3.38).5 A 2016 review of the existing evidence by an expert panel in Canada found that in T2DM trials, the incidence of DKA was estimated to be 0.160.76 per 1000 patient-years and patients could present with normal blood glucose levels.7 A case series found that about 70% of patients presenting with DKA were euglycemic.7 Overall, data from trials showed that DKA asssociated with SGLT-2 inhibitors occurred more commonly in patients who were dependent on insulin.7 Adverse event databases have also shown that DKA is associated with use of SGLT-2 inhibitors, with over 200 DKA events in adults reported with canagliflozin in Canada11 and 8968 cases of DKA associated with canagliflozin, dapagliflozin or empagliflozin reported in the US,12 of which 15 involved patients under age 18, of whom 3 had T2DM.12 More cases of DKA associated with use of SGLT-2 inhibitors may have gone unreported, and further study in the pediatric population is needed
I discussed Ozempic as a sort of cultural shorthand earlier this year in Health Populi
This approach is ideal for those seeking faster results or who have significantly diminished HGH levels, offering a more direct route to enhanced vitality
Days 628, 30.0 nmol/kg/day
The 500 mg mark is often seen as a "sweet spot"it provides enough of the compound to support the bodys natural stores without exceeding the levels typically used in safety studies
Smith HZ, Hollingshead CM, Kendall B
